Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole was unchanged today. By the end of trading, Onyx Pharmaceuticals rose $2.74 (3.3%) to $86.17 on average volume. Throughout the day, 1.2 million shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock ranged in a price between $84.02-$87.70 after having opened the day at $84.02 as compared to the previous trading day's close of $83.43. Other companies within the Drugs industry that increased today were:
), up 15.7%,
), up 14.3%,
), up 9.8%, and
), up 8.7%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $6.1 billion and is part of the health care sector. Shares are up 10.6% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and two rate it a hold.
TheStreet Ratings rates Onyx Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow.
- You can view the full Onyx Ratings Report.
On the negative front,
), down 19.8%,
), down 15.1%,
), down 13%, and
), down 12.3%, were all laggards within the drugs industry with
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.
It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE